SECENDS - GILD

2025

Q4 4 filings

Nov

General Counsel Departed

Deborah H. Telman out Dec 5, 2025

8-K

Nov

Q3 2025 Results

Unable to extract specific revenue and EPS figures from provided XBRL taxonomy data

10-Q

Oct

Q3 2025 Earnings

Q3 2025 financial results announced

8-K

Oct

Biktarvy Patent Settlement

No generic entry until April 1, 2036

8-K

Q3 4 filings

Aug

New Principal Accounting Officer

Erin Burkhart appointed SVP Controllership, effective Sept 22, 2025

8-K

Aug

Q2 2025 Results

Financial data not available in provided content

10-Q

Aug

Q2 2025 Earnings

Q2 2025 financial results announced

8-K

Aug

Amended Bylaws

Board approved amended bylaws on July 30, 2025

8-K

Q2 3 filings

May

2025 Annual Shareholder Meeting

9 directors elected, executive compensation approved, 4 shareholder proposals rejected

8-K

May

Q1 2025 Results

Financial data not available in provided XBRL structure

10-Q

Apr

Q1 2025 Earnings

Q1 2025 financial results announced

8-K

Q1 4 filings

Mar

2025 Proxy Statement

Annual meeting: May 7, 2025, HIV sales: $19.6B (+8% YoY)

DEF 14A

Mar

Chief Accounting Officer Departed

Sandra Patterson out, Diane Wilfong interim CAO

8-K

Feb

FY2024 2024 Results

Revenue and EPS data not visible in provided XBRL metadata

📌 Unable to extract specific milestones - financial figures and narrative content not available in metadata structure

10-K

Feb

Q4 2024 Earnings

Financial results for quarter and year ended December 31, 2024

8-K

2024

Q4 3 filings

Nov

Debt Offering

$3.5B senior notes: $750M 2029s at 4.80%, $1B 2035s at 5.10%, $1B 2054s at 5.50%, $750M 2064s at 5.60%

8-K

Nov

Q3 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q

Nov

Q3 2024 Earnings

Q3 2024 financial results announced

8-K

Q3 3 filings

Aug

Q2 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q

Aug

Q2 2024 Earnings

Q2 2024 financial results for quarter ended June 30, 2024

8-K

Jul

CMO Departure

Merdad V. Parsey, M.D., Ph.D. leaving, transition through Q1 2025

8-K

Q2 3 filings

May

Annual Shareholder Meeting Results

9 directors elected, officer exculpation amendment approved, 3 shareholder proposals rejected

8-K

May

Q1 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL data

10-Q

Apr

Q1 2024 Earnings

Q1 2024 financial results announced

8-K

Q1 6 filings

Mar

2024 Proxy Statement

Annual Meeting: May 8, 2024, 7 proposals including director elections and executive compensation

DEF 14A

Mar

Acquired CymaBay Therapeutics

$4.3B deal at $32.50 per share

8-K

Mar

Director Retirement

Kevin E. Lofton retiring from Board at May 8, 2024 annual meeting

8-K

Feb

FY2023 2023 Results

Unable to extract complete financial data from provided XBRL format

📌 Unable to extract specific milestone from provided XBRL metadata format

10-K

Feb

Acquired CymaBay Therapeutics

$32.50 per share, $151.6M termination fee

8-K

Feb

Q4 2023 Earnings

Financial results for quarter and year ended December 31, 2023

8-K